Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CMV PROPHYLAXIS IN HIGH-RISK RENAL-TRANSPLANT PATIENTS (D+ R-) BY ACYCLOVIR WITH OR WITHOUT HYPERIMMUNE (CMV) IMMUNOGLOBULINS - A PROSPECTIVE-STUDY/
Autore:
ROSTAING L; MARTINET O; CISTERNE JM; ICART J; CHABANNIER MH; DURAND D;
Indirizzi:
CHU RANGUEIL,SERV NEPHROL,UNITE TRANSPLANTAT ORGANES,1 AVE JEAN POUILHES F-31054 TOULOUSE FRANCE CHU RANGUEIL,DEPT NEPHROL,TRANSPLANTAT UNIT F-31054 TOULOUSE FRANCE CHU RANGUEIL,VIROL LAB F-31054 TOULOUSE FRANCE
Titolo Testata:
American journal of nephrology
fascicolo: 6, volume: 17, anno: 1997,
pagine: 489 - 494
SICI:
0250-8095(1997)17:6<489:CPIHRP>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
PRIMARY CYTOMEGALOVIRUS DISEASE; CONTROLLED TRIAL; IMMUNE GLOBULIN; ORAL ACYCLOVIR; VIRUS-VACCINE; RECIPIENTS; INFECTION; ALLOGRAFTS; PREVENTION; REJECTION;
Keywords:
RENAL TRANSPLANTATION; ACYCLOVIR; CYTOMEGALOVIRUS; ANTICYTOMEGALOVIRUS; IMMUNOGLOBULINS; REJECTION; IMMUNOSUPPRESSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
L. Rostaing et al., "CMV PROPHYLAXIS IN HIGH-RISK RENAL-TRANSPLANT PATIENTS (D+ R-) BY ACYCLOVIR WITH OR WITHOUT HYPERIMMUNE (CMV) IMMUNOGLOBULINS - A PROSPECTIVE-STUDY/", American journal of nephrology, 17(6), 1997, pp. 489-494

Abstract

In this prospective randomized study including 28 patients, we show that, in cytomegalovirus (CMV)-seronegative renal transplant recipients(R-) receiving a CMV-seropositive graft (D+), high doses of acyclovir(ACV, i.e. 3,200 mg/day) during the first 3 months after transplantation were as efficient as hyperimmune CMV immunoglobulins (CMV Igs) plus high doses of ACV regarding the prophylaxis of CMV primoinfection. Fifty-four percent of the patients in the ACV arm and 50% in the other arm presented at least one episode of viremia (n.s.). The incidence ofCMV disease was 31% in the ACV group and 20% in the ACV + CMV Ig group (n.s.). By comparison with historical controls (no prophylaxis), we found that ACV with or without CMV Ig significantly delayed and significantly decreased the rate of CMV disease, although the severity scorewas not statistically different. Moreover, high doses of ACV were farless expensive than their combination with hyperimmune CMV Igs. Thus,until oral ganciclovir is available for the prophylaxis of primary CMV infection in renal transplant patients, we recommend the use of highdoses of ACV for the first 3 months after transplantation in high-risk renal transplant patients, i.e. D+/R-.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/09/20 alle ore 20:50:56